Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:18:20.295Z.
Calculation as of: 2026-10-06T21:18:20.295Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a19952d2edecd783a1a7aa32ab0a3489a492a6ad3733958836c0f0d47bc8061
PE RATIO
N/A
Spruce Biosciences, Inc.
Market Cap
$117.76M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $117.76M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A |
| Cibus, Inc. (CBUS)vs › | $119.84M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A |
| Seer, Inc. (SEER)vs › | $120.41M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$42.78
Forward EPS (Est.)
$-25.74
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
